Group 1 - The core point of the news is that Guangji Pharmaceutical's stock reached a limit-up on November 24, closing at 7.83 yuan per share, with a total market value of 2.715 billion yuan and a trading volume of 50.81 million yuan [1][2] Group 2 - The stock movement is attributed to its involvement in the vitamin B2 sector, where it is a major global supplier, and its production of children's medication that alleviates symptoms of common colds and influenza [2] - The company has a state-owned background, with its controlling shareholder being Changjiang Industrial Investment Group, ultimately controlled by the Hubei Provincial State-owned Assets Supervision and Administration Commission [2] Group 3 - For the period from January to September 2025, Guangji Pharmaceutical reported an operating income of 429 million yuan, a year-on-year decrease of 7.12%, and a net profit attributable to shareholders of -97.2986 million yuan, which represents a year-on-year increase of 38.64% [2]